Tebu-Bio to Distribute TriLink's CleanAmp Hot-Start PCR Products in Europe | GenomeWeb

TriLink BioTechnologies said today that Tebu-Bio will market its CleanAmp products for hot-start PCR in Europe.

Tebu-Bio is a distributor headquartered in Le-Perray-en-Yvelines, France, with offices in Belgium, Germany, Italy, the Netherlands, Portugal, Denmark, Spain, and the UK.

TriLink, based in San Diego, Calif., said that the agreement extends a previous deal, in place for more than 10 years, under which Tebu-Bio has sold its modified nucleoside triphosphates and custom oligonucleotides.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.